Prostate carcinoma
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Based on data from genome‑wide association study of the Consortium for Chinese Consortium for Prostate Cancer Genetics, rs1815009 and rs2684788 inside 3'UTR of insulin‑like growth factor 1 receptor (IGF1R) presented significant genotype distribution between PCa and control samples.
|
30365147 |
2019 |
Prostate carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
IGF1R and AXL were identified as potential targets of miR-139 based on multiple miRNA-binding sites in 3'-untranslated regions of both the genes and their association with prostate cancer growth pathways.
|
31269290 |
2019 |
Prostate carcinoma
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
The NEAT1, SRC3, and IGF1R were highly expressed in the patients' samples of prostate cancer.
|
29225160 |
2018 |
Prostate carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
Collectively, we proposed a novel model for an IDH1R132H-microRNAs-IGF1R regulatory axis, which might provide insight into the function of IDH1R132H in PCa development.
|
29331887 |
2018 |
Prostate carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
Prostate carcinoma is highly dependent on the IGF/IGF-IR/IRS axis.
|
30338032 |
2018 |
Prostate carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
Our study demonstrates that antrocin sensitizes PCa to radiation through constitutive suppression of IGF-1R downstream signaling, revealing that it can be developed as a potent therapeutic agent to overcome radioresistant PCa.
|
30602706 |
2018 |
Prostate carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
It is well known that Src tyrosine kinase, insulin-like growth factor 1 receptor (IGF-IR), and focal adhesion kinase (FAK) play important roles in prostate cancer (PrCa) development and progression.
|
27232975 |
2017 |
Prostate carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
Inhibition of the insulin-like growth factor-1 receptor potentiates acute effects of castration in a rat model for prostate cancer growth in bone.
|
28447314 |
2017 |
Prostate carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
Insulin-like growth factor 1 receptor affects the survival of primary prostate cancer patients depending on TMPRSS2-ERG status.
|
28545426 |
2017 |
Prostate carcinoma
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
The insulin-like growth factor-1 receptor (IGF1R) plays a key role in cell growth and tumorigenesis, and is overexpressed in most malignancies, including prostate cancer.
|
27285981 |
2016 |
Prostate carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
Both IGF1R and INSR Knockdown Exert Antitumorigenic Effects in Prostate Cancer In Vitro and In Vivo.
|
26452103 |
2015 |
Prostate carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
Our study underscores the oncogenic impact of IGF1R including significant effects on tumor growth, cell migration, sensitivity to apoptotic/chemotherapeutic agents and angiogenesis, and characterizes the INSR, in particular the isoform INSRA, as additional cancer-promoting receptor in prostate cancer.
|
24809298 |
2014 |
Prostate carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
To ascertain the biological significance of this hypothesis, we focused on IGF1R, a known prostate cancer growth factor that is induced by androgen and directly targeted by the miR-99a/let7c/125b-2 cluster.
|
23503464 |
2014 |
Prostate carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
IGF2 mRNA but not IGF2 receptor mRNA expression was increased in patient samples during progression to castrate-resistant PC as was immunoreactivity to INSR and IGF1R antibodies.
|
23319492 |
2013 |
Prostate carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
Activation of epidermal growth factor receptor (EGFR), type 1 insulin-like growth factor receptor (IGF1R), and crosstalk between these two signaling pathways have been implicated in the development of radiation resistance in PC.
|
23950876 |
2013 |
Prostate carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
Proportional hazard models were used to assess PTEN expression and its interaction with IGF-IR, in relation to lethal prostate cancer (cancer-specific death or distant metastases).
|
23983239 |
2013 |
Prostate carcinoma
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
The miRNA let-7a1 inhibits the expression of insulin-like growth factor 1 receptor (IGF1R) in prostate cancer PC-3 cells.
|
23974362 |
2013 |
Prostate carcinoma
|
0.300 |
PosttranslationalModification
|
disease |
BEFREE |
IGF-I receptor phosphorylation is impaired in cathepsin X-deficient prostate cancer cells.
|
23152410 |
2012 |
Prostate carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
Global methylation analysis identifies PITX2 as an upstream regulator of the androgen receptor and IGF-I receptor genes in prostate cancer.
|
22495974 |
2012 |
Prostate carcinoma
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Taken together, these results suggest that EGR-1 may stimulate prostate cancer cell growth through up-regulation of IGF-1R and indicate that down-regulation of EGR-1 could be an effective therapeutic approach against prostate cancer.
|
22115966 |
2012 |
Prostate carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
Selected growth factor/growth factor receptor loops (mainly TGFα/EGFR and IGFs/IGFIR) have been proposed as regulators of prostate cancer cell growth.
|
21887406 |
2011 |
Prostate carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
Plasma and tissue insulin-like growth factor-I receptor (IGF-IR) as a prognostic marker for prostate cancer and anti-IGF-IR agents as novel therapeutic strategy for refractory cases: a review.
|
21782884 |
2011 |
Prostate carcinoma
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
In addition, lycopene treatment enhanced the growth-inhibitory effect of docetaxel more effectively on DU145 cells with IGF-IR high expression than on those PCa cell lines with IGF-IR low expression.
|
21403837 |
2011 |
Prostate carcinoma
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Our results suggest that prostate cancer progression is associated with a decrease in IGF-IR expression that could be the result of impaired ability of AR to stimulate IGF-IR gene expression.
|
20417685 |
2010 |
Prostate carcinoma
|
0.300 |
PosttranslationalModification
|
disease |
BEFREE |
The methylation status of the AR and IGF1R genes was evaluated in a series of prostate cancer cell lines corresponding to early (benign) and advanced (metastatic) stages of the disease.
|
20338164 |
2010 |